MedTrace Logo

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

NCT06736275 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.

Conditions

Interventions

DRUG

SXRN

SXRN is a naked plasmid DNA drug targeting miRNA.

DRUG

Placebo

Matching placebo, same dosing regimen (IV infusion once daily for 14 days)

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Jiangsu GQ Pharma Co., Ltd.

    collaborator UNKNOWN

  • Jiangsu Nutai Biologics Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2027-10-06
Completion
2027-12-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06736275 on ClinicalTrials.gov